Vis enkel innførsel

dc.contributor.authorLevine, Myron M
dc.contributor.authorAbdullah, Salim
dc.contributor.authorArabi, Yyaseen M.
dc.contributor.authorDarko, Delese Mimi
dc.contributor.authorDurbin, Anna P
dc.contributor.authorEstrada, Vicente
dc.contributor.authorJamrozik, Euzebiusz
dc.contributor.authorKremsner, Peter G
dc.contributor.authorLagos, Rosanna
dc.contributor.authorPitisuttithum, Punnee
dc.contributor.authorPlotkin, Stanley A
dc.contributor.authorSauerwein, Robert
dc.contributor.authorShi, Sheng-Li
dc.contributor.authorSommerfelt, Halvor
dc.contributor.authorSubbarao, Kanta
dc.contributor.authorTreanor, John J
dc.contributor.authorVrati, Sudhanshu
dc.contributor.authorKing, Deborah
dc.contributor.authorBalasingam, Shobana
dc.contributor.authorWeller, Charlie
dc.contributor.authorAguilar, Anastazia Older
dc.contributor.authorCassetti, M. Cristina
dc.contributor.authorKrause, Philip R
dc.contributor.authorRestrepo, Ana Maria Henao
dc.date.accessioned2022-03-01T07:04:58Z
dc.date.available2022-03-01T07:04:58Z
dc.date.created2022-01-25T12:37:09Z
dc.date.issued2021
dc.identifier.issn1058-4838
dc.identifier.urihttps://hdl.handle.net/11250/2981897
dc.description.abstractWHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.en_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleViewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteersen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2020en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1093/cid/ciaa1290
dc.identifier.cristin1989429
dc.source.journalClinical Infectious Diseasesen_US
dc.source.pagenumber2035-2041en_US
dc.identifier.citationClinical Infectious Diseases. 2021, 72 (11), 2035-2041.en_US
dc.source.volume72en_US
dc.source.issue11en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal